IP Library Granted Patent US 8,097,599
Granted Patent B2
US 8,097,599 · App. 12/794,184 · Granted Jan 17, 2012

Plasmid encoding feline BMP-7

Assignee: Merial Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,599
App. No.
12/794,184
Granted
Jan 17, 2012
Kind
B2
Abstract

The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in humans, dogs and cats, by intra-vascular kidney administration of the recombinant vectors and pharmaceutical compositions of the invention.

Claims (9)

1. A recombinant plasmid vector comprising a polynucleotide encoding a BMP-7 polypeptide having at least 99% sequence identity to SEQ ID NO:19.

2. A recombinant plasmid vector comprising a polynucleotide encoding a mature BMP-7 polypeptide having at least 98.5% sequence identity to the amino acid sequence of residues 293-431 of SEQ ID NO:19.

3. The recombinant plasmid vector of claim 1 , wherein the polynucleotide has the sequence as set forth in SEQ ID NO: 17 or 18.

4. The recombinant plasmid vector of any one of claims 1 , 2 , and 3 , wherein the BMP-7 polypeptide comprises a heterologous signal peptide.

5. The recombinant plasmid vector of any one of claims 1 , 2 , and 3 , wherein the polynucleotide is operably linked to a promoter.

6. The recombinant plasmid vector of claim 1 , wherein the plasmid is pMEB039 having the sequence as set forth in SEQ ID NO:20.

7. The recombinant plasmid vector of claim 5 , wherein the promoter is a CMV IE promoter.

8. A method of treating a mammalian subject suffering from, or at risk of developing, renal failure, comprising administering to a portal vein, hepatic vein or renal vein of said mammalian subject a therapeutically effective amount of the recombinant plasmid vector of any one of claims 1 , 2 , 5 , 6 and 7 , wherein the recombinant plasmid vector further comprises a cytomegalovirus immediate early (CMV IE) promoter.

9. A pharmaceutical composition comprising a recombinant plasmid vector of any one of claims 1 , 2 , 5 , 6 and 7 , and optionally at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2015
From: MERIAL LIMITED
To: MERIAL, INC.
Reel/Frame 035014/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2011
From: FISCHER, LAURENT BERNARD
To: MERIAL LIMITED
Reel/Frame 026375/0649 →
Continuity (5)
Continuation 11803991 · May 16, 2007
Continuation In Part 11801798 · May 11, 2007
Continuation In Part 11599026 · Nov 14, 2006
Provisional Application 60736452 · Nov 14, 2005
Related Publication 20100261782A1 · Oct 14, 2010